Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Tumor cell migration and invasion play fundamental roles in cancer metastasis. The mammalian target of rapamycin (mTOR), a highly conserved and ubiquitously expressed serine/threonine (Ser/Thr) kinase, is a central regulator of cell growth, proliferation, differentiation and survival. Recent studies have shown that mTOR also plays a critical role in the regulation of tumor cell motility, invasion and cancer metastasis. Current knowledge indicates that mTOR functions as two distinct complexes, mTORC1 and mTORC2. mTORC1 phosphorylates p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), and regulates cell growth, proliferation, survival and motility. mTORC2 phosphorylates Akt, protein kinase C α (PKCα) and the focal adhesion proteins, and controls the activities of the small GTPases (RhoA, Cdc42 and Rac1), and regulates cell survival and the actin cytoskeleton. Here we briefly review recent knowledge of mTOR complexes and the role of mTOR signaling in tumor cell migration and invasion. We also discuss recent efforts about the mechanism by which rapamycin, a specific inhibitor of mTOR, inhibits cell migration, invasion and cancer metastasis.

[1]  Baoshan Xu,et al.  Rapamycin Inhibits IGF-1 Stimulated Cell Motility through PP2A Pathway , 2010, PloS one.

[2]  D. Sutherlin,et al.  Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. , 2010, Bioorganic & medicinal chemistry letters.

[3]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[4]  B. Li,et al.  Rapamycin inhibits lung metastasis of B16 melanoma cells through down‐regulating alphav integrin expression and up‐regulating apoptosis signaling , 2010, Cancer science.

[5]  E. Otsuji,et al.  A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy , 2009, Molecular Cancer.

[6]  F. Lang,et al.  Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation , 2009, Journal of Molecular Medicine.

[7]  Sara M. Johnson,et al.  Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. , 2009, Anticancer research.

[8]  S. Whitehead,et al.  Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  Kevin Curran,et al.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. , 2009, Cancer research.

[10]  A. Nègre-Salvayre,et al.  Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. , 2009, Atherosclerosis.

[11]  Zuquan Zou,et al.  A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. , 2009, International journal of molecular medicine.

[12]  E. Schleußner,et al.  mTOR mediates human trophoblast invasion through regulation of matrix-remodeling enzymes and is associated with serine phosphorylation of STAT3. , 2009, Experimental cell research.

[13]  M. Pepper,et al.  IL-20 activates human lymphatic endothelial cells causing cell signalling and tube formation. , 2009, Microvascular research.

[14]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[15]  D. Sabatini,et al.  DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.

[16]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[17]  Francis J Giles,et al.  Targeting the mTOR pathway using deforolimus in cancer therapy. , 2009, Future oncology.

[18]  T. Efferth,et al.  Molecular principles of cancer invasion and metastasis (review). , 2009, International journal of oncology.

[19]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[20]  D. Pearce,et al.  Rictor/TORC2 Regulates Caenorhabditis elegans Fat Storage, Body Size, and Development through sgk-1 , 2009, PLoS biology.

[21]  G. Ruvkun,et al.  Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. , 2009, Genes & development.

[22]  Q. Wang,et al.  Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9 , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  N. Webster,et al.  Curcumin disrupts the Mammalian target of rapamycin-raptor complex. , 2009, Cancer research.

[24]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[25]  Jeffrey W. Clark,et al.  Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Chopp,et al.  Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. , 2009, Journal of experimental therapeutics & oncology.

[27]  D. Alessi,et al.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.

[28]  Kai Huang,et al.  Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. , 2008, Neoplasia.

[29]  L. Siu,et al.  First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting , 2008, Journal of hematology & oncology.

[30]  Shile Huang,et al.  Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins , 2008, Oncogene.

[31]  N. Demartines,et al.  mTORC2 regulates PGE2-mediated endothelial cell survival and migration. , 2008, Biochemical and biophysical research communications.

[32]  J. Masri,et al.  Hsp70 associates with Rictor and is required for mTORC2 formation and activity. , 2008, Biochemical and biophysical research communications.

[33]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[34]  R. Lin,et al.  Rapamycin and mTOR kinase inhibitors , 2008, Journal of chemical biology.

[35]  J. Dipersio,et al.  A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies , 2008, Clinical Cancer Research.

[36]  Zhiwei Wang,et al.  Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. , 2008, Cancer research.

[37]  B. Rini,et al.  Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin , 2008, Clinical Cancer Research.

[38]  P. Houghton,et al.  mTORC1 Signaling Can Regulate Growth Factor Activation of p44/42 Mitogen-activated Protein Kinases through Protein Phosphatase 2A* , 2008, Journal of Biological Chemistry.

[39]  Joseph Gera,et al.  mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. , 2007, Cancer research.

[40]  A. Mercurio.  Faculty Opinions recommendation of Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. , 2007 .

[41]  Robert T Abraham,et al.  Targeting the mTOR signaling network in cancer. , 2007, Trends in molecular medicine.

[42]  T. Griffin,et al.  PRR5, a Novel Component of mTOR Complex 2, Regulates Platelet-derived Growth Factor Receptor β Expression and Signaling* , 2007, Journal of Biological Chemistry.

[43]  J. Gutkind,et al.  P-Rex1 Links Mammalian Target of Rapamycin Signaling to Rac Activation and Cell Migration* , 2007, Journal of Biological Chemistry.

[44]  K. Guan,et al.  Expanding mTOR signaling , 2007, Cell Research.

[45]  D. Alessi,et al.  Identification of Protor as a novel Rictor-binding component of mTOR complex-2. , 2007, The Biochemical journal.

[46]  Samy Lamouille,et al.  Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway , 2007, The Journal of cell biology.

[47]  R. Roth,et al.  PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding* , 2007, Journal of Biological Chemistry.

[48]  H. Sakurai,et al.  Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. , 2007, European journal of cancer.

[49]  M. Miyazaki,et al.  Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis , 2007, Cancer science.

[50]  C. Heeschen,et al.  Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. , 2007, Kidney international.

[51]  S. Carr,et al.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. , 2007, Molecular cell.

[52]  MeOst.  Rapamycin Selectively Inhibits the Growth of Childhood Rhabdomyosarcoma Cells through Inhibition of Signaling via the Type I Insulin-like Growth Factor Receptor I , 2007 .

[53]  S. French,et al.  Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. , 2006, The Journal of investigative dermatology.

[54]  J. Blenis,et al.  Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways , 2006, Oncogene.

[55]  Jacob D. Jaffe,et al.  mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s , 2006, Current Biology.

[56]  Shile Huang,et al.  Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells , 2006, International journal of cancer.

[57]  A. Tangoku,et al.  The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer , 2006, British Journal of Cancer.

[58]  A. Wong,et al.  Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. , 2006, Endocrinology.

[59]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[60]  M. Skobe,et al.  Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. , 2006, Cancer research.

[61]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[62]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[63]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[64]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[65]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[66]  Steven P. Gygi,et al.  mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.

[67]  R. Loewith,et al.  Tor2 Directly Phosphorylates the AGC Kinase Ypk2 To Regulate Actin Polarization , 2005, Molecular and Cellular Biology.

[68]  K. Alitalo,et al.  Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. , 2005, Cancer research.

[69]  S. Hollenbeck,et al.  Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. , 2005, American journal of physiology. Heart and circulatory physiology.

[70]  J. Kunz,et al.  The pleckstrin homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2. , 2005, Molecular biology of the cell.

[71]  L. Helman,et al.  Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. , 2005, Cancer research.

[72]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[73]  N. Sonenberg,et al.  Regulation of cap-dependent translation by eIF4E inhibitory proteins , 2005, Nature.

[74]  H. Hong,et al.  Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. , 2005, Investigative ophthalmology & visual science.

[75]  S. Bao,et al.  The activation of Akt/PKB signaling pathway and cell survival , 2005, Journal of cellular and molecular medicine.

[76]  D. A. Hanson,et al.  Focal adhesion kinase: in command and control of cell motility , 2005, Nature Reviews Molecular Cell Biology.

[77]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[78]  A. Parsons,et al.  Genome‐wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton , 2004, The EMBO journal.

[79]  Dianne Miller,et al.  Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. , 2004, Experimental cell research.

[80]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[81]  M. Crouch,et al.  Role of the p70S6K pathway in regulating the actin cytoskeleton and cell migration , 2004 .

[82]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[83]  Stefano Fumagalli,et al.  S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.

[84]  K. V. van Golen,et al.  Rho-Regulatory Proteins in Breast Cancer Cell Motility and Invasion , 2004, Breast Cancer Research and Treatment.

[85]  D. Boffa,et al.  Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[86]  H. Lane,et al.  Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells , 2004, Cancer Research.

[87]  K. Reddy,et al.  Role of MAP kinase in tumor progression and invasion , 2003, Cancer and Metastasis Reviews.

[88]  M. Crouch,et al.  Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. , 2004, Experimental cell research.

[89]  M. Young,et al.  Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants , 2004, Clinical & Experimental Metastasis.

[90]  P. Houghton,et al.  Resistance to Rapamycin: A Novel Anticancer Drug , 2004, Cancer and Metastasis Reviews.

[91]  R. O'Connor,et al.  Regulation of IGF-I Receptor Signaling in Tumor Cells , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[92]  J. Gomez-Cambronero.  Rapamycin inhibits GM‐CSF‐induced neutrophil migration , 2003, FEBS letters.

[93]  J. Pestana,et al.  Simultaneous pancreas-kidney transplantation initial experience. , 2003, Transplantation proceedings.

[94]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[95]  Paul Tempst,et al.  GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. , 2003, Molecular cell.

[96]  F. Luan,et al.  Rapamycin is an effective inhibitor of human renal cancer metastasis. , 2003, Kidney international.

[97]  Michael N. Hall,et al.  TOR signalling in bugs, brain and brawn , 2003, Nature Reviews Molecular Cell Biology.

[98]  N. Kleckner,et al.  The ATRs, ATMs, and TORs Are Giant HEAT Repeat Proteins , 2003, Cell.

[99]  B. Karlan,et al.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. , 2003, Cancer research.

[100]  I. Jung,et al.  Cdc42 and Rac1 are necessary for autotaxin‐induced tumor cell motility in A2058 melanoma cells , 2002, FEBS letters.

[101]  Hua Tang,et al.  Transduction of Growth or Mitogenic Signals into Translational Activation of TOP mRNAs Is Fully Reliant on the Phosphatidylinositol 3-Kinase-Mediated Pathway but Requires neither S6K1 nor rpS6 Phosphorylation , 2002, Molecular and Cellular Biology.

[102]  In-Hyun Park,et al.  Regulation of Ribosomal S6 Kinase 2 by Mammalian Target of Rapamycin* , 2002, The Journal of Biological Chemistry.

[103]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[104]  P. Brennan,et al.  Regulation of an Activated S6 Kinase 1 Variant Reveals a Novel Mammalian Target of Rapamycin Phosphorylation Site* , 2002, The Journal of Biological Chemistry.

[105]  F. Luan,et al.  Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1 , 2002, Transplantation.

[106]  E. Hafen,et al.  dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1 , 2002, Nature cell biology.

[107]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[108]  George Thomas,et al.  Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[109]  J. Blenis,et al.  Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. , 2002, Advances in cancer research.

[110]  Michael D Schaller,et al.  Paxillin: a focal adhesion-associated adaptor protein , 2001, Oncogene.

[111]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[112]  D R Alessi,et al.  PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? , 2001, Journal of cell science.

[113]  S. Marx,et al.  Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. , 2001, Circulation.

[114]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[115]  Brian A. Hemmings,et al.  Protein Kinase SGK Mediates Survival Signals by Phosphorylating the Forkhead Transcription Factor FKHRL1 (FOXO3a) , 2001, Molecular and Cellular Biology.

[116]  J. Avruch,et al.  The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. , 2001, Progress in molecular and subcellular biology.

[117]  M. Kastan,et al.  Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1 , 2000, Nature Cell Biology.

[118]  M. Mareel,et al.  Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3‐kinase‐, Rho‐, and Rac‐dependent signaling pathways , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  O. Shah,et al.  4E-BP1 and S6K1: translational integration sites for nutritional and hormonal information in muscle. , 2000, American journal of physiology. Endocrinology and metabolism.

[120]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[121]  P. Friedl,et al.  The biology of cell locomotion within three-dimensional extracellular matrix , 2000, Cellular and Molecular Life Sciences CMLS.

[122]  S. Schreiber,et al.  Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[123]  J. Heitman,et al.  The TOR signaling cascade regulates gene expression in response to nutrients. , 1999, Genes & development.

[124]  Michael N. Hall,et al.  The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors , 1999, Nature.

[125]  Kenta Hara,et al.  Immunopurified Mammalian Target of Rapamycin Phosphorylates and Activates p70 S6 Kinase α in Vitro * , 1999, The Journal of Biological Chemistry.

[126]  E. Hafen,et al.  Drosophila S6 kinase: a regulator of cell size. , 1999, Science.

[127]  T. Seufferlein,et al.  Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.

[128]  G. Brunn,et al.  Mutational analysis of sites in the translational regulator, PHAS‐I, that are selectively phosphorylated by mTOR , 1999, FEBS letters.

[129]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[130]  Linda N. Liu,et al.  Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. , 1999, Cancer research.

[131]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[132]  K. Tomizawa,et al.  Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. , 1998, Biochemical and biophysical research communications.

[133]  M. Chan,et al.  In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. , 1998, Biochemical pharmacology.

[134]  R. Abraham,et al.  Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. , 1998, Current opinion in immunology.

[135]  A. Gingras,et al.  4E-BP3, a New Member of the Eukaryotic Initiation Factor 4E-binding Protein Family* , 1998, The Journal of Biological Chemistry.

[136]  P. Keely,et al.  Integrins and GTPases in tumour cell growth, motility and invasion. , 1998, Trends in cell biology.

[137]  S. Snyder,et al.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[138]  M. Andjelkovic,et al.  Phosphorylation and activation of p70s6k by PDK1. , 1998, Science.

[139]  Dario R. Alessi,et al.  3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro , 1998, Current Biology.

[140]  M. Hall,et al.  Signaling to the actin cytoskeleton. , 1998, Annual review of cell and developmental biology.

[141]  L. Peso,et al.  Rho proteins induce metastatic properties in vivo , 1997, Oncogene.

[142]  G. Thomas,et al.  TOR signalling and control of cell growth. , 1997, Current opinion in cell biology.

[143]  M. Kasuga,et al.  Regulation of eIF-4E BP1 Phosphorylation by mTOR* , 1997, The Journal of Biological Chemistry.

[144]  L. Liotta,et al.  General mechanisms of metastasis , 1997, Cancer.

[145]  R. Pearson,et al.  Dual requirement for a newly identified phosphorylation site in p70s6k , 1997, Molecular and cellular biology.

[146]  Christine C. Hudson,et al.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. , 1997, Science.

[147]  M. Crouch,et al.  Regulation of thrombin-induced stress fibre formation in Swiss 3T3 cells by the 70-kDa S6 kinase. , 1997, Biochemical and biophysical research communications.

[148]  Marc Bickle,et al.  The Yeast Phosphatidylinositol Kinase Homolog TOR2 Activates RHO1 and RHO2 via the Exchange Factor ROM2 , 1997, Cell.

[149]  G. Petruzzelli,et al.  Endothelial cell response to human head and neck squamous cell carcinomas involves downregulation of protein phosphatases-1/2A, cytoskeletal depolymerization and increased motility. , 1997, Invasion & metastasis.

[150]  M. Hall,et al.  TOR2 is required for organization of the actin cytoskeleton in yeast. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[151]  J. Badimón,et al.  Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.

[152]  T. Seufferlein,et al.  Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. , 1996, Cancer research.

[153]  S. Schreiber,et al.  A Signaling Pathway to Translational Control , 1996, Cell.

[154]  Stuart L. Schreiber,et al.  Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP , 1996, Science.

[155]  D. Lauffenburger,et al.  Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.

[156]  R. Pearson,et al.  The principal target of rapamycin‐induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. , 1995, The EMBO journal.

[157]  S. Schreiber,et al.  PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints , 1995, Science.

[158]  S. Schreiber,et al.  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[159]  R. Abraham,et al.  Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.

[160]  V. Berlin,et al.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[161]  A. Nairn,et al.  Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[162]  N. Sonenberg,et al.  PHAS-I as a link between mitogen-activated protein kinase and translation initiation. , 1994, Science.

[163]  A. Gingras,et al.  Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function , 1994, Nature.

[164]  K. Nakanishi,et al.  A putative sirolimus (rapamycin) effector protein. , 1994, Biochemical and biophysical research communications.

[165]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[166]  N. Sato,et al.  ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons , 1994, The Journal of cell biology.

[167]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[168]  G. Thomas,et al.  Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[169]  M. Mclaughlin,et al.  Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity , 1993, Molecular and cellular biology.

[170]  J. Kunz,et al.  Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression , 1993, Cell.

[171]  K. Sakaguchi,et al.  The ezrin-like family of tyrosine kinase substrates: receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation. , 1993, Oncogene.

[172]  J. Avruch,et al.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. , 1992, Science.

[173]  G. Thomas,et al.  A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[174]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[175]  A. Bretscher,et al.  cDNA cloning and sequencing of the protein‐tyrosine kinase substrate, ezrin, reveals homology to band 4.1. , 1989, The EMBO journal.

[176]  L. Liotta,et al.  Tumour motility factors. , 1988, Cancer surveys.

[177]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[178]  J. Douros,et al.  New antitumor substances of natural origin. , 1981, Cancer treatment reviews.

[179]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[180]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.